{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:11:18Z","timestamp":1778897478207,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1K23EY025729-01"],"award-info":[{"award-number":["1K23EY025729-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006920","name":"University of Pennsylvania","doi-asserted-by":"publisher","award":["2P30EYEY001583"],"award-info":[{"award-number":["2P30EYEY001583"]}],"id":[{"id":"10.13039\/100006920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008556","name":"Paul MacKall and Evanina Bell MacKall Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008556","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.oret.2019.05.016","type":"journal-article","created":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T21:09:36Z","timestamp":1558732176000},"page":"41-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Determinants in Initial Treatment Choice for Diabetic Macular Edema"],"prefix":"10.1016","volume":"4","author":[{"given":"Brian L.","family":"VanderBeek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt","family":"Scavelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinxi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2019.05.016_bib1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/IAE.0b013e3182695b83","article-title":"Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema: results of the Pan-American Collaborative Retina Study Group at 24 months","volume":"33","author":"Arevalo","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.oret.2019.05.016_bib2","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1001\/archophthalmol.2012.393","article-title":"A\u00a02-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3","volume":"130","author":"Rajendram","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2019.05.016_bib3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000331322","article-title":"Comparison of grid laser, intravitreal triamcinolone, and intravitreal bevacizumab in the treatment of diffuse diabetic macular edema","volume":"227","author":"Sobaci","year":"2012","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.oret.2019.05.016_bib4","first-page":"1","article-title":"Ranibizumab for Edema of the Macula in Diabetes Study: 3-year outcomes and the need for prolonged frequent treatment","author":"Do","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2019.05.016_bib5","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.ophtha.2012.08.022","article-title":"Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results","volume":"119","author":"Elman","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.05.016_bib6","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.05.016_bib7","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ajo.2013.11.012","article-title":"Management paradigms for diabetic macular edema","volume":"157","author":"Mitchell","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2019.05.016_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149450","article-title":"Trends in the care of diabetic macular edema: analysis of a national cohort","volume":"11","author":"VanderBeek","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.oret.2019.05.016_bib9","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2147\/OPTH.S60893","article-title":"Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema","volume":"8","author":"Kiss","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2019.05.016_bib10","series-title":"Annual survey of employer health benefits","year":"2012"},{"key":"10.1016\/j.oret.2019.05.016_bib11","first-page":"222","article-title":"Healthcare spending and preventive care in high-deductible and consumer-directed health plans","volume":"17","author":"Beeuwkes Buntin","year":"2011","journal-title":"Am J Managed Care"},{"key":"10.1016\/j.oret.2019.05.016_bib12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5034\/inquiryjrnl_44.1.26","article-title":"Consumer-directed health plans: new evidence on spending and utilization","volume":"44","author":"Feldman","year":"2007","journal-title":"Inquiry"},{"key":"10.1016\/j.oret.2019.05.016_bib13","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1377\/hlthaff.27.4.1111","article-title":"The impact of consumer-directed health plans on prescription drug use","volume":"27","author":"Greene","year":"2008","journal-title":"Health Affairs (Project Hope)"},{"key":"10.1016\/j.oret.2019.05.016_bib14","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1111\/j.1475-6773.2011.01252.x","article-title":"Effect of switching to a high-deductible health plan on use of chronic medications","volume":"46","author":"Reiss","year":"2011","journal-title":"Health Services Research"},{"key":"10.1016\/j.oret.2019.05.016_bib15","first-page":"45","article-title":"How patient cost-sharing trends affect adherence and outcomes: a literature review","volume":"37","author":"Eaddy","year":"2012","journal-title":"P\u00a0T"},{"key":"10.1016\/j.oret.2019.05.016_bib16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/MLR.0000000000000008","article-title":"Impact of a high-deductible health plan on outpatient visits and associated diagnostic tests","volume":"52","author":"Reddy","year":"2014","journal-title":"Medical Care"},{"key":"10.1016\/j.oret.2019.05.016_bib17","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/jamaophthalmol.2017.1595","article-title":"Accuracy of billing codes used in the therapeutic care of diabetic retinopathy","volume":"135","author":"Lau","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2019.05.016_bib18","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1001\/archopht.126.7.986","article-title":"Identification of patients with diabetic macular edema from claims data: a validation study","volume":"126","author":"Bearelly","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2019.05.016_bib19","first-page":"15","article-title":"Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization","volume":"14","author":"Young","year":"2008","journal-title":"Am J Managed Care"},{"key":"10.1016\/j.oret.2019.05.016_bib20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ophtha.2018.09.025","article-title":"Rewarding cost efficiency in medicare\u2019s merit-based incentive payment system","volume":"126","author":"Glasser","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.05.016_bib21","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.oret.2018.11.014","article-title":"Treatment patterns for patients with recently diagnosed diabetic macular edema","volume":"3","author":"Moulin","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2019.05.016_bib22","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/jamaophthalmol.2014.369","article-title":"Trends over time and regional variations in the rate of laser trabeculoplasty in the Medicare population","volume":"132","author":"Jampel","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2019.05.016_bib23","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.ophtha.2005.02.010","article-title":"Variations in treatment among adult-onset open-angle glaucoma patients","volume":"112","author":"Friedman","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.05.016_bib24","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ophtha.2015.10.017","article-title":"Geographic variation in the use of diagnostic testing of patients with newly diagnosed open-angle glaucoma","volume":"123","author":"Elam","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.05.016_bib25","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jamaophthalmol.2015.5322","article-title":"Geographic variation in the rate and timing of cataract surgery among US communities","volume":"134","author":"Kauh","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2019.05.016_bib26","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/09286586.2012.698692","article-title":"Cataract surgery among Medicare beneficiaries","volume":"19","author":"Schein","year":"2012","journal-title":"Ophthalmic Epidemiol"},{"key":"10.1016\/j.oret.2019.05.016_bib27","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.ajo.2011.11.034","article-title":"Regional practice patterns for retinal detachment repair in the United States","volume":"153","author":"Hwang","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2019.05.016_bib28","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.ophtha.2016.02.015","article-title":"High variation of intravitreal injection rates and medicare anti-vascular endothelial growth factor payments per injection in the United States","volume":"123","author":"Erie","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.05.016_bib29","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ajo.2017.10.010","article-title":"Geographic and demographic variation in use of ranibizumab versus bevacizumab for neovascular age-related macular degeneration in the United States","volume":"184","author":"Gower","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2019.05.016_bib30","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3928\/23258160-20180329-05","article-title":"Frequency of bevacizumab and ranibizumab injections for diabetic macular edema in medicare beneficiaries","volume":"49","author":"Wu","year":"2018","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.oret.2019.05.016_bib31","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1001\/archopht.1985.01050120030015","article-title":"Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1","volume":"103","year":"1985","journal-title":"Arch Ophthalmol"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653019301976?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653019301976?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:36:47Z","timestamp":1778895407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653019301976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S2468653019301976"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2019.05.016","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determinants in Initial Treatment Choice for Diabetic Macular Edema","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2019.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}